Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | GALR1 | P47211 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL639462 | 0.98 | KDM4E (0.53) | KDM4EGAAGFERTDP1MAPT | |
| SCHEMBL640257 | 0.84 | GFER (0.49) | KDM4EGAAGFERTDP1MAPT | |
| SCHEMBL638661 | 0.82 | GFER (0.50) | KDM4EGAAGFERTDP1MAPT | |
| SCHEMBL639698 | 0.80 | GFER (0.51) | KDM4EGAAGFERTDP1MAPT | |
| SCHEMBL2246612 | 0.74 | HDAC8 (0.35) | KDM4EGAAGFERTDP1MAPT | |
| SCHEMBL59138 | 0.72 | NOTUM (0.55) | KDM4EGAATDP1MAPTKMT2A | |
| SCHEMBL2243279 | 0.72 | GFER (0.38) | KDM4EGAAGFERMAPTHDAC8 | |
| SCHEMBL2247757 | 0.72 | HDAC8 (0.36) | KDM4EGAAGFERHDAC8 | |
| SCHEMBL2250817 | 0.70 | GFER (0.39) | KDM4EGAAGFERMAPTHDAC8 | |
| SCHEMBL3344780 | 0.70 | GAA (0.64) | KDM4EGAAGFERMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119674-B2 | 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-21 | — | — | US | claimed |
| US-20100144814-A1 | NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | claimed |
| EP-2155693-A1 | NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | Galderma Research & Development (FR) | 2010-02-24 | — | — | EP | claimed |
| WO-2008152331-A9 | NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-23 | — | — | WO | claimed |
| WO-2008152331-A1 | NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | claimed |
| US-8119674-B2 | 4-phenylimidazole-2-thione tyrosinase inhibitors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-21 | — | — | US | disclosed |
| US-20100144814-A1 | NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-2155693-A1 | NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | Galderma Research & Development (FR) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008152331-A9 | NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-23 | — | — | WO | disclosed |
| WO-2008152331-A1 | NOVEL 4-PHENYL-IMIDAZOLE-2-THIONES USED AS TYROSINASE INHIBITORS, METHOD FOR PREPARING SAME AND USE THEREOF IN HUMAN MEDICINE AND COSMETOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144814-A1 | NOVEL 4-PHENYLIMIDAZOLE-2-THIONE TYROSINASE INHIBITORS AND PHARMACEUTICAL/COSMETIC APPLICATIONS THEREOF | TYR, TH, PAH | KDM4E 582/4885GAA 115/4885GFER 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.